Sumanta Pal: A massive effort to characterize the activity of Debio1347 by Petros Grivas and colleagues

Petros Grivas shared a post by Sumanta Pal on X/Twitter:

“Thanks Sumanta Pal for highlighting our work with Keith Flaherty and many stellar colleagues for a basket trial across FGFR-fused cancers! Trying to learn from all trials dissecting into biology!”

Quoting Sumanta Pal’s post:

“Congrats to Petros Grivas, Fred Hutchinson Cancer Center and colleagues for a terrific paper out now in Clinical Cancer Research. A massive effort to characterize the activity of Debio1347, a novel FGFR inhibitor. 63 patients enrolled in total with a RR of 5%; 45% with SD. Lots of rich information in this paper with rich transcriptomic data provided across the cohort.”

Source: Petros Grivas/X and Sumanta Pal/X

Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Sumanta (Monty) Pal, MD, is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles. He serves as the co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.